DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
GV20 received an upfront payment and is eligible for additional milestone payments
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The antibody was designed and developed at Abzena’s Cambridge, UK,
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Subscribe To Our Newsletter & Stay Updated